United Asset Strategies Inc. Invests $829,000 in Zoetis Inc. $ZTS

United Asset Strategies Inc. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 5,665 shares of the company’s stock, valued at approximately $829,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. HB Wealth Management LLC boosted its position in shares of Zoetis by 2.5% during the 3rd quarter. HB Wealth Management LLC now owns 18,134 shares of the company’s stock worth $2,653,000 after purchasing an additional 434 shares in the last quarter. Childress Capital Advisors LLC raised its stake in Zoetis by 20.7% during the 3rd quarter. Childress Capital Advisors LLC now owns 3,552 shares of the company’s stock worth $520,000 after buying an additional 609 shares during the period. Cerity Partners LLC boosted its holdings in Zoetis by 14.2% in the third quarter. Cerity Partners LLC now owns 371,198 shares of the company’s stock worth $54,314,000 after acquiring an additional 46,137 shares in the last quarter. First Merchants Corp boosted its holdings in Zoetis by 2.1% in the third quarter. First Merchants Corp now owns 27,094 shares of the company’s stock worth $3,964,000 after acquiring an additional 547 shares in the last quarter. Finally, Galvin Gaustad & Stein LLC grew its stake in Zoetis by 28.2% in the third quarter. Galvin Gaustad & Stein LLC now owns 88,124 shares of the company’s stock valued at $12,894,000 after acquiring an additional 19,406 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.9%

NYSE ZTS opened at $126.77 on Friday. The business’s fifty day moving average is $123.63 and its 200-day moving average is $140.93. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The stock has a market capitalization of $55.87 billion, a price-to-earnings ratio of 21.34, a PEG ratio of 2.55 and a beta of 0.97. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zoetis in a research note on Monday, December 29th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a report on Monday, December 15th. JPMorgan Chase & Co. lowered their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, KeyCorp began coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus price target of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.